BridgeMD
Tacrolimus monotherapy in elderly kidney transplant recipients
EU CTIS ID: 2024-517709-10-00
What this study is testing
Lowering the immune suppressive maintenance regimen in the elderly recipient thereby reducing infection-related mortality and morbidity
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - patients of 60 years or older receiving a deceased or living kidney transplant and at time of transplantation no donor-specific anti-HLA antibodies. - Re-transplantations are allowed when meeting the before mentioned criteria. - Patients have to give written informed consent to participate in the study.
You likely can't join if
- - HLA-identical living-related transplantation - the presence of an immunological-mediated disease requiring immunosuppression - ABO-blood group incompatibility or positive CDC-test with the donor as performed at the HLA lab of the participating UMC - presence of donor-specific anti-HLA antibodies as defined by the Luminex assay (presence defined as MFI above background level) - combined liver/kidney or pancreas/kidney transplantation or previous organ transplantation other than kidney - participation in another clinical trial interfering with immune suppressive medication or risk of infection - not able to stop prednisone because of long-term use - eGFR <25 ml/min at month 3 - within the first 3 months after transplantation: any biopsy-proven rejection requiring T cell depletion or biopsy-proven antibody-mediated rejection - not able to provided written informed consent
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.